A bicyclic peptide ligand specific to Nectin-4

JP2026097846APending Publication Date: 2026-06-16BICYCLETX LTD
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
BICYCLETX LTD
Filing Date
2026-02-12
Publication Date
2026-06-16

Smart Images

  • Figure 2026097846000130
    Figure 2026097846000130
  • Figure 2026097846000131
    Figure 2026097846000131
  • Figure 2026097846000132
    Figure 2026097846000132
Patent Text Reader

Abstract

The present invention provides a method for providing information for identifying or selecting cancer patients for treatment with a nectin-4 targeted drug conjugate, and a pharmaceutical composition comprising a nectin-4 targeted drug conjugate for use in blocking, suppressing, or treating cancer in a subject. [Solution] A method for providing information for identifying or selecting cancer patients for treatment with a nectin-4 targeted drug conjugate, i) the step of determining the copy number of nectin-4 in a tumor-derived sample from a patient; and ii) A method is provided which, if it is determined in step i) that the patient has more than 2 copies of nectin-4, includes the step of identifying or selecting the patient for treatment with a nectin-4 targeted drug conjugate.
Need to check novelty before this filing date? Find Prior Art

Claims

1. A peptide ligand specific to nectin-4, comprising at least two loop molecules A polypeptide containing at least three cysteine ​​residues separated by columns, and a small amount At least two polypeptide loops are formed on the molecular scaffold. Peptide containing a molecular scaffold that forms a covalent bond with the cysteine ​​residue of the peptide Drigands or pharmaceutically acceptable salts thereof.

2. The aforementioned loop sequence consists of 3, 6, 7, 8, or 9 amino acids, for example, 3, 6, 7, or 9 A peptide ligand according to claim 1, comprising 1 amino acids, particularly 3 or 9 amino acids. 。

3. The aforementioned loop sequence consists of two parts: one part is made up of three amino acids and the other part is made up of nine amino acids. The claim according to claim 1 or 2, comprising three cysteine ​​residues separated by two loop sequences. The peptide ligand listed.

4. C ｉ -P / A / Hyp-F / Y-G / A-C ｉｉ -X １ -X ２ -X ３ -W / 1-Nal / 2-Nal-S / A-X ４ -P-I / D / A-W / 1-Nal / 2-Nal-C ｉｉｉ (Sequence ID 38); C ｉ -W / A-P-L-D / S-S / D-Y-W-C ｉｉ -X ５ -R-I-C ｉｉｉ ( Sequence ID 39); C ｉ -V-T-T-S-Y-D-C ｉｉ -F / W-L / V-H / R / T-L-L / G- G / Q / H-C ｉｉｉ (Sequence No. 40); C ｉ -X ６ -X ７ -X ８ -C ｉｉ -X ９ -X １０ -X １１ -X １２ -X １３ -X １４ - X １５ -X １６ -X １７ -C ｉｉｉ (Sequence ID 41); and C ｉ -W / A / Y-P / A-L-D / S / A-S / D / P / A-Y-W / 1-Nal- C ｉｉ -X ５ -R / HArg / A-I-C ｉｉｉ (Sequence ID 42); A peptide ligand according to claim 1 or 2, comprising an amino acid sequence selected from (In the formula, X １ ~X ５ represents any amino acid residue, including modified and non-natural amino acids; X ６ Gly;Pro or azetidine (Aze), hydroxyproline (HyP), 4-amino-proline (Pro(4NH)), oxazolidine-4-carboxylic acid (Oxa ), octahydroindolecarboxylic acid (Oic) or 4,4-difluoroproline Non-natural derivatives of Pro selected from (4,4-DFP); Ala or aminoisobutyric acid A non-natural derivative of Ala selected from (Aib); or representing sarcosine (Sar); X ７ Phe or 3-methylphenylalanine (3MePhe), 4-methyl- Phenylalanine (4MePhe), homophenylalanine (HPhe), 4,4-biphenylalanine Nylalanine (4,4-BPA) or 3,4-dihydroxyphenylalanine (D Non-natural derivatives of Phe selected from OPA; Tyr; or Ala or 1-naphthi Lualanine (1-Na), 2-naphthylalanine (2-Na), or 2-pyridyl Represents a non-natural derivative of Ala selected from alanine (2Pal); X ８ is Gly;Ala;Asp;Lys or acetyl-lysine (KAc or Lys (Ac)) non-natural derivatives of Lys selected from; Phe; Glu; Glun; Leu; S er; Arg; or represents cysteic acid (Cya); X ９ It does not exist, or it is selected from Met or methionine sulfone (Met(O2)). Selected non-natural derivatives of Met; selected from Gln or homoglutamine (HGln) Non-natural derivatives of Glun; Leu or homoleucine (HLeu) or norleucine (Nle) Non-natural derivatives of Leu selected from: Lys; Ile; t-butyl-alani n(tBuAla); or homoserine-methyl(HSe(Me)); X １０ It is derived from Pro;Lys or acetyl-lysine (KAc or Lys(Ac)). Selected non-natural derivatives of Lys; Arg or 2-amino-4-guanidinobutyric acid (Ag b) Selected from homoarginine (HArg) or N-methyl-homoarginine Unnatural derivatives of Arg; Glu; Ser; Asp; Gln; Ala; Hydroxyproline (HyP); or representing cysteic acid (Cya); X １１ This is a non-natural derivative of Asn selected from Asn or N-methyl-asparagine. ;Thr;Asp;Gly;Ser;His;Ala or thienyl-alanine (Th ), 2-(1,2,4-triazole-1-yl)-alanine(1,2,4-TriAz Al selected from ) or beta-(4-thiazolyl)-alanine (4ThiAz) a non-natural derivative of a; Lys; or represents cysteic acid (Cya); X １２ This is Trp or azatryptophan (AzaTrp), 5-fluoro-L-tri Selected from tryptophan (5FTrp) or methyl-tryptophan (TrpMe) non-natural derivatives of Trp; or Al or 1-naphthylalanine (1-Na) ku represents a non-natural derivative of Al selected from 2-naphthylalanine (2-Naal); X １３ This refers to a non-natural derivative of Ser selected from Ser or homoserine (HSer); Ala; Asp; or Thr; X １４ This is a non-Trp selected from Trp or azatryptophan (AzaTrp). Natural derivatives; Ser; Ala or 2-(1,2,4-triazole-1-yl)-ala nin (1,2,4-TriAz), 1-naphthylalanine (1-Na) or 2-naph Chillalanine (2-Na); a non-natural derivative of Ala selected from Asp; Phe also Phe is a non-natural substance selected from 3,4-dihydroxyphenylalanine (DOPA). Derivatives; Tyr; Unnatural derivatives of Thr selected from Tyr or N-methyl-threonine Conductor; tetrahydropyran-4-propanoic acid (THP(O)); or dioxo-4-te Represents trahydrothiopyranylacetic acid (THP(SO2)); X １５ This is Pro or azetidine (Aze), pipecolic acid (Pip), or oxa Represents a non-natural derivative of Pro selected from zolidine-4-carboxylic acid (Oxa); X １６ Il is selected from Ile or N-methyl-isoleucine (NMeIle). Non-natural derivatives of e; Ala or 3-cyclohexyl-alanine (Cha) or cyclo Non-natural derivatives of Ala selected from propyl-alanine (Cpa); Pro or Hi Non-natural derivatives of Pro selected from droxyproline (HyP); Asp; Lys; Si Clopentyl-glycine (C5A); tetrahydropyran-4-propanoic acid (THP(O) )); or represent dioxo-4-tetrahydrothiopyranylacetic acid (THP(SO2)) ； X １７ This is Trp or azatryptophan (AzaTrp) or 5-fluoro-L - Unnatural derivatives of trp selected from tryptophan (5FTrp); Phe; Tyr ;1-naphthylalanine (1-Na); or 2-naphthylalanine (2-Na) Representation; Hyp represents hydroxyproline, 1-Naal represents 1-naphthylalanine, and 2- Nal represents 2-naphthylalanine, HArg represents homoarginine, and Ci and C ｉｉ and C ｉｉｉ This refers to the first, second, and third cysteine ​​residues, or these pharmaceutically acceptable residues. (Each represents the amount of salt to be contained.)

5. The aforementioned loop sequence consists of a first loop sequence made of three amino acids and a second loop sequence made of It contains three cysteine ​​residues separated by two loop sequences consisting of nine amino acids. fruit, C ｉ -X ６ -X ７ -X ８ -C ｉｉ -X ９ -X １０ -X １１ -X １２ -X １３ -X １４ -X １５ -X １６ -X １７ -C ｉｉｉ (Sequence No. 41); (Here, X ６ From X １７ (The amino acids selected from are defined in claim 4) A peptide ligand according to claim 4, comprising a sequence.

6. X ６ However, Pro or azetidine (Aze), hydroxyproline (HyP), 4-A Mino-proline (Pro(4NH)), oxazolidine-4-carboxylic acid (Oxa), O 4,4-difluoroproline (4, 4-DFP)m represents a non-natural derivative of Pro selected from m, for example, Pro; and / or Taha X ７ However, Phe or 3-methylphenylalanine (3MePhe), 4-methyl- Phenylalanine (4MePhe), homophenylalanine (HPhe), 4,4-biphenylalanine Nylalanine (4,4-BPA) or 3,4-dihydroxyphenylalanine (D Non-natural derivatives of Phene selected from OPA; Ala or 1-naphthylalanine (1 2-Naphthylalanine (2Na) or 2-pyridylalanine (2P A non-natural derivative of Ala selected from al, e.g., Phe or 1-naphthylalanine. (1-Na), in particular representing 1-naphthylalanine (1-Na); and / or X ８ This includes Asp, Arg, Lys, or cysteic acid (Cya), for example, D-Asp, D- Represents Arg, D-Lys or D-Cya, especially D-Asp; and / or X ９ However, non-methionine sulfone (Met(O2)) selected from Met or methionine sulfone (Met(O2)) Natural derivatives; or Leu or homoleucine (HLeu) or norleucine (Nl e) Non-natural derivatives of Leu selected from, e.g., Met or Leu, in particular Met shi; and / or X １０ However, Arg or 2-amino-4-guanidinobutyric acid (Agb), homoarginine ( A non-natural derivative of Arg selected from HArg or N-methyl-homoarginine; Or cysteic acid (Cya), for example homoarginine (HArg) or cysteic acid (Cya) (e.g., D-Cya), especially homoarginine (HArg); and / or Taha X １１ However, non-natural derivatives of Asn selected from Asn or N-methyl-asparagine. ;Asp; or His; or cysteic acid (Cya), e.g., Asn, Asp, Hi s or cysteic acid (Cya) (e.g., D-Cya), especially Asp; and / or Taha X １２ However, Trp or azatryptophan (AzaTrp), 5-fluoro-L-tri Selected from tryptophan (5FTrp) or methyl-tryptophan (TrpMe) non-natural derivatives of Trp, for example, representing Trp; and / or X １３ However, non-natural derivatives of Ser selected from Ser or homoserine (HSer), For example, it represents Ser; and / or X １４ However, non-natural derivatives of Thr selected from Thr or N-methyl-tyronine, e.g. For example, it represents Thr; and / or X １５ represents Pro; and / or X １６ However, Il selected from Ile or N-methyl-isoleucine (NMeIle) A non-natural derivative of e; or P selected from Pro or hydroxyproline (HyP). Unnatural derivatives of ro, e.g., Ile; or Pro or hydroxyproline (HyP) Non-natural derivatives of Pro selected from, particularly Ile, Pro or hydroxyproline ( HyP), more specifically representing hydroxyproline (HyP); and / or X １７ However, Trp or azatryptophan (AzaTrp) or 5-fluoro-L - Unnatural derivatives of Trp selected from tryptophan (5FTrp), for example, Trp A peptide ligand according to claim 4 or 5.

7. The aforementioned loop sequence consists of a first loop sequence made of three amino acids and a second loop sequence made of It contains three cysteine ​​residues separated by two loop sequences consisting of nine amino acids. fruit, C ｉ -P-X ７ -X ８ -C ｉｉ -X ９ -HArg-X １１ -W-S-T-P-X １６ -W -C ｉｉｉ (Sequence No. 204) (Here, X ７ , X ８ , X ９ , X １１ and X １６ are as defined in claim 4 or 6 The P Petit ligand.

8. The aforementioned loop sequence consists of a first loop sequence made of three amino acids and a second loop sequence made of It contains three cysteine ​​residues separated by two loop sequences consisting of nine amino acids. fruit, C ｉ -P-F / 1-Nal-dD / dR-C ｉｉ -M / L-HArg-N / H / D-W- S-T-P-I / P / HyP-W-C ｉｉｉ amino acids selected from (SEQ ID NO: 205) A peptide ligand according to any one of claims 4 to 7, comprising a sequence.

9. C ｉ -X ６ -X ７ -X ８ -C ｉｉ -X ９ -X １０ -X １１ -X １２ -X １３ -X １４ - X １５ -X １６ -X １７ -C ｉｉｉ The peptide ligand of (SEQ ID NO: 41) CPFGCMETWSWPIWC (Sequence ID 45); CPFGCMRGWSWPIWC (Sequence ID 46); CPFGCMSGWSWPIWC (Sequence ID 47); CPFGCMEGWSWPIWC (Sequence ID 48); CPFGCMEDWSWPIWC (Sequence ID 49); CPFGCMPGWSWPIWC (Sequence ID 50); CPFGCMKSWSWPIWC (Sequence ID 51); CPFGCMKTWSWPIWC (Sequence ID 52); CPFGCMKGWSWPIWC (Sequence ID 53); CPFGCQEHWSWPIWC (Sequence ID 54); CPFGCIKSWSWPIWC (Sequence ID 55); CPFGCQEDWSWPIWC (Sequence ID 56); CPFGCMSDWSWPIWC (Sequence ID 57); CPFGCM[HArg]NWSWPIWC (Sequence ID 59); CPFGCM[K(Ac)]NWSWPIWC(Sequence ID 60); CPFGCM[K(Ac)]SWSWPIWC(Sequence ID 61); CPFGC[Nle]KSWSWPPIWC (Sequence ID 62); CPFGCM[HArg]SWSWPIWC (Sequence ID 63); CPFGCM[dK]SWSWPIWC (Sequence ID 64); CP[dA]GCMKNWSWPIWC (Sequence ID 66); CPF[dA]CMKNWSWPIWC (Sequence ID 67); CPFGCM[dA]NWSWPIWC (Sequence ID 68); CPFGCMK[dA]WSWPIWC (Sequence ID 69); CPFGCMKN[dA]SWPIWC (Sequence ID 70); CPFGCMKNWSWP[dA]WC (Sequence ID 71); C[dA]FGCMKNWSWPIWC (Sequence ID 72); CPFGC[tBuAla]KNWSWPIWC (Sequence ID 73); CPFGC[HLeu]KNWSWPIWC (Sequence ID 74); CPFGCMKNWSWPI[1Naal]C (Sequence ID 75); CPF[dD]CM[HArg]NWSWPIWC (Sequence ID 76); CPF[dA]CM[HArg]NWSWPIWC (Sequence ID 77); CP[3MePhe]GCMKNWSWPIWC (Sequence ID 78); CP[4MePhe]GCMKNWSWPIWC (Sequence ID 79); CP[HPhe]GCMKNWSWPIWC (Sequence ID 80); CPF[dD]CMKNWSWPIWC (Sequence ID 81); CPFGC[Hse(Me)]KNWSWPIWC (Sequence ID 82); CPFGCMKN[AzaTrp]SWPIWC (Sequence ID 83); CPFGCMKNWSFPPIWC (Sequence ID 84); CPFGCMKNWSYPIWC (Sequence ID 85); CPFGCMKNWS[1Naal]PIWC (Sequence ID 86); CPFGCMKNWS[2Na]PIWC (Sequence ID 87); CPFGCMKNWS[AzaTrp]PIWC (Sequence ID 88); CPFGCMKNWSW[Aze]IWC (Sequence ID 89); CPFGCMKNWSW[Pip]IWC (Sequence ID 90); CPFGCMKNWSWPIFC (Sequence ID 91); CPFGCMKNWSWPIYC (Sequence ID 92); CPFGCMKNWSWPI[AzaTrp]C (Sequence ID 93); CGFGCMKNWSWPIWC (Sequence ID 94); C[Aze]FGCMKNWSWPIWC (Sequence ID 95); CPF[K(Ac)]CMKNWSWPIWC (Sequence ID 96); CPFGCLKNWSWPIWC (Sequence ID 97); CPFGC[MetO2]KNWSWPIWC (Sequence ID 98); CPFGCMPNWSWPIWC (Sequence ID 99); CPFGCMQNWSWPIWC (Sequence ID 100); CPFGCMKNWSWPPPWC (Sequence ID 101); CP[2Pal]GCMKNWSWPIWC (Sequence ID 102); CPFGCMKN[1Na]SWPIWC (Sequence ID 111); CPFGCMKN[2Na]SWPIWC (Sequence ID 112); CPFGCMKNWSWPI[2Na]C (Sequence ID 113); C[HyP]FGCMKNWSWPIWC (Sequence ID 114); CPF[dD]CM[HArg]NWSTPIWC (Sequence ID 115); CPF[dD]CM[HARG][dK]WSTPIWC (Sequence ID 116); CPF[dD]CM[HArg]NWSTPKWC (Sequence ID 117); C[Pro(4NH)]F[dD]CM[HArg]NWSTPIWC(Sequence ID 118) ）； CPF[dD]CMKNWSTPIWC (Sequence ID 119); CPF[dK]CM[HArg]NWSTPIWC (Sequence ID 120); CPF[dD]CK[HArg]NWSTPIWC (Sequence ID 121); CPF[dD]CM[HArg]KWSTPIWC (Sequence ID 122); C[Oxa][F[dD]CM[HArg]NWSTPIWC (Sequence ID 123); CPF[dD]CM[HARG][Thi]WSTPIWC (Sequence ID 124); CPF[dD]CM[HARG][4ThiAz]WSTPIWC (Sequence ID 125); CPF[dD]CM[HARG][124TriAz]WSTPIWC(Sequence ID 126) ）； CPF[dD]CM[HArg]NWS[124TriAz]PIWC(Sequence ID 127) ）； CPF[dD]CM[HARG]NWST[Oxa]IWC (Sequence ID 128); CP[DOPA][dD]CM[HArg]NWSTPIWC (Sequence ID 129); CPF[dD]CM[HARG]NWS[DOPA]PIWC (Sequence ID 130); CPF[dD]CM[HArg]NWS[THP(SO2)]PIWC(Sequence ID 131) ）； CPF[dD]CM[HArg]NWSTP[THP(SO2)]WC(Sequence ID 132) ）； CPF[dD]CM[HArg]N[5FTrp]STPIWC (Sequence ID 133); CPF[dD]CM[HArg]NWSTPI[5FTrp]C (Sequence ID 134); CPF[dD]CM[HArg]NWS[THP(O)]PIWC (Sequence ID 135); CPF[dD]CM[HARG]NWSTP[THP(O)]WC (Sequence ID 136); C[44DFP]F[dD]CM[HArg]NWSTPIWC (Sequence ID 137); C[Oic][F[dD]CM[HArg]NWSTPIWC (Sequence ID 138); CPF[dF]CM[HArg]NWSTPIWC (Sequence ID 139); CPF[dE]CM[HARG]NWSTPIWC (Sequence ID 140); CPF[dQ]CM[HArg]NWSTPIWC (Sequence ID 141); CPF[dL]CM[HArg]NWSTPIWC (Sequence ID 142); CPF[dS]CM[HArg]NWSTPIWC (Sequence ID 143); CPF[dD]CM[HArg]NW[HSer]TPIWC (Sequence ID 144); CPF[dD]CM[HArg]NWSTP[C5A]WC (Sequence ID 145); CPF[dD]CM[HArg]NWSTP[Cpa]WC (Sequence ID 146); CPF[dD]CM[HArg]NWSTP[Cha]WC (Sequence ID 147); CPF[dD][C[HGln][HArg]NWSTPIWC (Sequence ID 148); CPF[dD]C[C5A][HArg]NWSTPIWC (Sequence ID 149); CPF[dD]CM[HArg]N[Trp(Me)]STPIWC(Sequence ID 150) ； CPF[dD][NMeCys]M[HArg]NWSTPIWC (Sequence ID 151); CPF[dD]C[HArg]NWS[NMeThr]PIWC (Sequence ID 152); CP[1Nal][dD]CM[HArg]NWSTPIWC (Sequence ID 155); CP[2Nal][dD]CM[HArg]NWSTPIWC (Sequence ID 156); CP[44BPA][dD]CM[HArg]NWSTPIWC (Sequence ID 157); CPF[dD]CM[HArg]NWSTPWC (Sequence ID 158); CPF[dD]CM[HARG]NWSTP[HyP]WC (Sequence ID 159); CPF[dD]CL[HArg]NWSTPWC(Sequence ID 160); CPF[dD]CL[HArg]NWSTPIWC (Sequence ID 161); CPY[dD]CM[HARG]NWSTPIWC (Sequence ID 162); C[Aib][F[dD]CM[HArg]NWSTPIWC (Sequence ID 163); C[Sar][F[dD]CM[HArg]NWSTPIWC (Sequence ID 164); CPF[dR]CM[HArg]NWSTPIWC (Sequence ID 165); CPF[dD]CM[HArg]NWSTPKWC (Sequence ID 166); CP[1Nal][dD]CM[HArg]NWSTP[HyP]WC(Sequence ID 167) ）； CP[1Nal][dD]CM[HArg]HWSTP[HyP]WC(Sequence ID 168) ）： CP[1Nal][dD]CM[HArg]DWSTP[HyP]WC(Sequence ID 169) ）； CP[1Nal][dD]CM[HArg]DWSTPIWC (Sequence ID 170); CP[1Na][dR]CM[HArg]NWSTP[HyP]WC(Sequence ID 171) ）； CP[1Nal][dR]CM[HArg]HWSTP[HyP]WC(Sequence ID 172) ）； CPF[dD]CM[NMeHarg]NWSTPIWC (Sequence ID 173); CPF[dD]CM[HARG][NMeasn]WSTPIWC (Sequence ID 174); CPF[dD]CM[HARG]NWS[NMeThr]PIWC (Sequence ID 175); CPF[dD]CM[HARG]NWSTP[NMeIle]WC (Sequence ID 176); CP[1Nal][dD]CM[HArg][Cya]WSTP[HyP]WC(array number) No. 177); CP[1Nal][dD]CM[Cya]DWSTP[HyP]WC (Sequence ID 178) ； CP[1Nal][DCya]CM[HArg]DWSTP[HyP]WC(Sequence ID 1) ７９）； CP[1Nal][dD]CM[HArg]DWDTP[HyP]WC(Sequence ID 180) ）； CP[2Nal][dD]CM[HArg]DWSTP[HyP]WC(Sequence ID 181) ）； CP[1Nal][dD]CM[HArg]DWTTP[HyP]WC (Sequence ID 182) ）； CP[1Nal][dD]CM[HArg]DW[HSer]TP[HyP]WC(array) Number 183); CP[1Nal][dD]CM[HArg]DW[dS]TP[HyP]WC(Sequence ID) １８４）； CP[1Nal][dD]CM[HArg]DWSSP[HyP]WC(Sequence ID 185) ）； CP[1Na][dD]CM[Agb]DWSTP[HyP]WC (Sequence ID 186) ； CP[1Na][dD]CMPDWSTP[HyP]WC (Sequence ID 187); CP[1Nal][dD]CM[HyP]DWSTP[HyP]WC (Sequence ID 188) ； CP[1Nal][dR]CM[HArg]DWSTP[HyP]WC(Sequence ID 189) ）； CP[1Nal][dR]CM[HArg]DWDTP[HyP]WC(Sequence ID 190) ）； CP[2Nal][dR]CM[HArg]DWSTP[HyP]WC(Sequence ID 191) ）； CP[1Nal][dR]CM[HArg]DWTTP[HyP]WC (Sequence ID 192) ）； CP[1Nal][dR]CM[HArg]DW[HSer]TP[HyP]WC(array) Number 193); CP[1Nal][dR]CM[HArg]DW[dS]TP[HyP]WC(Sequence ID) １９４）； CP[1Nal][dR]CM[HArg]DWSSP[HyP]WC(Sequence ID 195) ）； CP[1Na][dR]CM[Agb]DWSTP[HyP]WC (Sequence ID 196) ； CP[1Na][dR]CMPDWSTP[HyP]WC (Sequence ID 197); CP[1Na][dR]CM[HyP]DWSTP[HyP]WC (Sequence ID 198) ； CP[1Na][dD]CL[HArg]DWSTPIWC (Sequence ID 199); CP[1Nal][dD]CL[HArg]DWSTP[HyP]WC(Sequence ID 200) ）； CP[1Nal][dR]CL[HArg]DWSTP[HyP]WC(Sequence ID 201) ）； CP[1Nal][dR]CL[HArg]HWSTP[HyP]WC(Sequence ID 202) ）； CP[1Na][dR]CM[HArg]DWSTPIWC (Sequence ID 203); CP[1Na][DCya]CM[Cya]DWSTP[HyP]WC(Sequence ID 20) ８）； CP[1Nal][DCya]CM[HArg][Cya]WSTP[HyP]WC (distribution Column number 209); CP[1Nal][dD]CM[Cya][Cya]WSTP[HyP]WC(Sequence ID) ２１０）； CP[1Nal][dK]CM[HArg]DWSTP[HyP]WC(Sequence ID 211) ）； CP[1Nal][dD]CMKDWSTP[HyP]WC (Sequence ID 212); CP[1Nal][dD]CM[HArg]D[dW]STP[HyP][dW]C (distribution Column number 215); and CPFGCM[HArg]DWSTP[HyP]WC (Sequence ID 216); For example, CP[1Nal][dD]CM[HArg]DWSTP[HyP]WC (array number) No. 169); In particular, DDA-(SEQ ID NO: 45)-A (referred to as BCY3386); DTA-(Sequence ID 46)-A (referred to as BCY3388); DSE-(Sequence ID 47)-A (referred to as BCY3389); HDA-(Sequence ID 48)-A (referred to as BCY3390); MDT-(Sequence ID 49)-A (referred to as BCY3391); DPG-(Sequence ID 50)-A (referred to as BCY3392); HDS-(Sequence ID 51)-A (referred to as BCY3393); (D-H)DS-(Sequence ID 51)-A (referred to as BCY7272); A-(Sequence ID 52)-TDK (referred to as BCY3394); A-(Sequence ID 53)-LKD (referred to as BCY3395); A-(Sequence ID 54)-TTA (referred to as BCY3396); A-(Sequence ID 55)-QME (referred to as BCY3397); A-(Sequence ID 56)-LSE (referred to as BCY3398); A-(Sequence ID 57)-STD (referred to as BCY3399); A-(Sequence ID 59)-TNK (referred to as BCY7265); Ac- (Sequence ID 59) (referred to as BCY7660); A-(Sequence ID 60)-TNK (referred to as BCY7266); Ac-(Sequence ID 60) (referred to as BCY7616); HDS-(Sequence ID 61)-A (referred to as BCY7273); HDS-(Sequence ID 62)-A (referred to as BCY7274); HDS-(Sequence ID 63)-A (referred to as BCY7275); HDS-(Sequence ID 64)-A (referred to as BCY7276); A-(Sequence ID 66)-TNK (referred to as BCY7349); A-(Sequence ID 67)-TNK (referred to as BCY7350); Ac-(Sequence ID 67) (referred to as BCY7538); A-(Sequence ID 68)-TNK (referred to as BCY7359); A-(Sequence ID 69)-TNK (referred to as BCY7360); A-(Sequence ID 70)-TNK (referred to as BCY7361); A-(Sequence ID 71)-TNK (referred to as BCY7365); A-(Sequence ID 72)-TNK (referred to as BCY7370); Ac-(Sequence ID 73) (referred to as BCY7535); Ac-(Sequence ID 74) (referred to as BCY7536); Ac-(Sequence ID 75) (referred to as BCY7541); [B-Ala] [Sar ５ ]- (Sequence ID 76) (referred to as BCY7556); Ac-[B-Ala][Sar ５ ]- (Sequence ID 76) (referred to as BCY7558); [B-Ala] [Sar ５ ]- (Sequence ID 77) (referred to as BCY7557); Ac-[B-Ala][Sar ５ ]- (Sequence ID 77) (referred to as BCY7559); Ac-(Sequence ID 78) (referred to as BCY7580); Ac-(Sequence ID 79) (referred to as BCY7581); Ac-(Sequence ID 80) (referred to as BCY7582); Ac-(Sequence ID 81) (referred to as BCY7584); Ac-(Sequence ID 82) (referred to as BCY7585); Ac-(Sequence ID 83) (referred to as BCY7588); Ac-(Sequence ID 84) (referred to as BCY7589); Ac-(Sequence ID 85) (referred to as BCY7590); Ac-(Sequence ID 86) (referred to as BCY7591); Ac-(Sequence ID 87) (referred to as BCY7592); Ac-(Sequence ID 88) (referred to as BCY7593); Ac-(Sequence ID 89) (referred to as BCY7594); Ac- (Sequence ID 90) (referred to as BCY7595); Ac-(Sequence ID 91) (referred to as BCY7596); Ac-(Sequence ID 92) (referred to as BCY7597); Ac-(Sequence ID 93) (referred to as BCY7598); Ac-(Sequence ID 94) (referred to as BCY7607); Ac- (Sequence ID 95) (referred to as BCY7608); Ac-(Sequence ID 96) (referred to as BCY7611); Ac-(Sequence ID 97) (referred to as BCY7612); Ac- (Sequence ID 98) (referred to as BCY7613); Ac-(Sequence ID 99) (referred to as BCY7614); Ac-(Sequence ID 100) (referred to as BCY7615); Ac-(Sequence ID 101) (referred to as BCY7618); Ac-(Sequence ID 102) (referred to as BCY7620); Ac-(Sequence ID 111) (referred to as BCY7663); Ac-(Sequence ID 112) (referred to as BCY7664); Ac-(Sequence ID 113) (referred to as BCY7667); Ac-(Sequence ID 114) (referred to as BCY7668); Ac-(Sequence ID 115) (referred to as BCY7765); (Sequence ID 115) (referred to as BCY7793); (MeO-dPEG12) (Sequence ID 115) (also known as BCY8087); (Carboxyfluorescein) (Sequence ID 115) (also known as BCY8208); (PEG ３ ) (PEG ３ ) (Sequence ID 115) (referred to as BCY7815); (MeO-dPEG12)(PEG3)(PEG3)(Sequence ID 115) (BCY80) (referred to as 94); Ac-DDD-(Sequence ID 115) (referred to as BCY8028); Ac-[ddD][ddD][ddD]-(Sequence ID 115) (referred to as BCY8029); [B-Ala][Sar10]-(Sequence ID 115) (referred to as BCY7814); Ac-(Sequence ID 116) (referred to as BCY7816); (MeO-dPEG12) (BCY) bound to Ac-(SEQ ID NO: 116)D-Lys6 (Also known as 8084); Ac-(Sequence ID 117) (referred to as BCY7817); Ac-(Sequence ID 118) (referred to as BCY7818); (MeO-dPEG12) bound to Ac-(SEQ ID NO: 118)Pro(4NH)1 ( (Referred to as BCY8086); Ac-(Sequence ID 119) (referred to as BCY7819); (MeO-dPEG12)(BCY80) is bound to Ac-(SEQ ID NO: 119)Lys5. (referred to as 88); Ac-(Sequence ID 120) (referred to as BCY7820); (MeO-dPEG12)(BCY80) conjugated to Ac-(SEQ ID NO: 120)Lys3 (referred to as 89); Ac-(Sequence ID 121) (referred to as BCY7821); (MeO-dPEG12)(BCY80) is bound to Ac-(SEQ ID NO: 121)Lys4. (referred to as 90); Ac-(Sequence ID 122) (referred to as BCY7822); (MeO-dPEG12)(BCY80) is bound to Ac-(SEQ ID NO: 122)Lys6. (referred to as 91); Ac-(Sequence ID 123) (referred to as BCY7876); Ac-(Sequence ID 124) (referred to as BCY7877); Ac-(Sequence ID 125) (referred to as BCY7879); Ac-(Sequence ID 126) (referred to as BCY7881); Ac-(Sequence ID 127) (referred to as BCY7883); Ac-(Sequence ID 128) (referred to as BCY7884); Ac-(Sequence ID 129) (referred to as BCY7886); Ac-(Sequence ID 130) (referred to as BCY7887); Ac-(Sequence ID 131) (referred to as BCY7889); Ac-(Sequence ID 132) (referred to as BCY7890); Ac-(Sequence ID 133) (referred to as BCY7891); Ac-(Sequence ID 134) (referred to as BCY7892); Ac-(Sequence ID 135) (referred to as BCY7894); Ac-(Sequence ID 136) (referred to as BCY7895); Ac-(Sequence ID 137) (referred to as BCY7896); Ac-(Sequence ID 138) (referred to as BCY7897); Ac-(Sequence ID 139) (referred to as BCY7902); Ac-(Sequence ID 140) (referred to as BCY7903); Ac-(Sequence ID 141) (referred to as BCY7904); Ac-(Sequence ID 142) (referred to as BCY7906); Ac-(Sequence ID 143) (referred to as BCY7907); Ac-(Sequence ID 144) (referred to as BCY7908); Ac-(Sequence ID 145) (referred to as BCY7911); Ac-(Sequence ID 146) (referred to as BCY7912); Ac-(Sequence ID 147) (referred to as BCY7913); Ac-(Sequence ID 148) (referred to as BCY7914); Ac-(Sequence ID 149) (referred to as BCY7915); Ac-(Sequence ID 150) (referred to as BCY7916); Ac-(Sequence ID 151) (referred to as BCY7973); Ac-(Sequence ID 152) (referred to as BCY7979); Ac- (Sequence ID 155) (referred to as BCY8030); Ac-(Sequence ID 156) (referred to as BCY8031); Ac-(Sequence ID 157) (referred to as BCY8032); Ac-(Sequence ID 158) (referred to as BCY8036); Ac-(Sequence ID 159) (referred to as BCY8037); Ac-(Sequence ID 160) (referred to as BCY8038); Ac-(Sequence ID 161) (referred to as BCY8039); Ac-(Sequence ID 162) (referred to as BCY8040); Ac-(Sequence ID 163) (referred to as BCY8041); Ac-(Sequence ID 164) (referred to as BCY8042); Ac-(Sequence ID 165) (referred to as BCY8042); Ac- (Sequence ID 166) (referred to as BCY8085); Ac-[B-Ala][Sar ５ ]- (Sequence ID 167) (referred to as BCY8120) ； Ac-(Sequence ID 167) (referred to as BCY8124); Ac-[B-Ala][Sar ５ ] - (Sequence ID 168) (referred to as BCY8121) ； Ac-(Sequence ID 168) (referred to as BCY8125); Ac-[B-Ala][Sar ５ ]- (Sequence ID 169) (referred to as BCY8122) ； Ac-(Sequence ID 169) (referred to as BCY8126); (Sequence ID 169) (referred to as BCY8116); Fluorescein (SEQ ID NO: 169) (also known as BCY8205); [B-Ala][Sar10]-(Sequence ID 169) (referred to as BCY8234); [PYA][B-Ala][Sar10]-(Sequence ID 169) (referred to as BCY8846) (to be); Ac-[B-Ala][Sar ５ ]- (Sequence ID 170) (referred to as BCY8123) ； Ac-(Sequence ID 170) (referred to as BCY8127); (Sequence ID 170) (referred to as BCY8206); Ac-(Sequence ID 171) (referred to as BCY8128); (Sequence ID 171) (referred to as BCY8207); [B-Ala][Sar10]-(Sequence ID 171) (referred to as BCY8232); Ac-(Sequence ID 172) (referred to as BCY8129); Ac-(Sequence ID 173) (referred to as BCY8153); Ac-(Sequence ID 174) (referred to as BCY8154); Ac-(Sequence ID 175) (referred to as BCY8157); Ac-(Sequence ID 176) (referred to as BCY8158); Ac-(Sequence ID 177) (referred to as BCY8161); Ac-[B-Ala][Sar10]-(Sequence ID 177) (referred to as BCY8278) ）； Ac-(Sequence ID 178) (referred to as BCY8162); Ac-[B-Ala][Sar10]-(Sequence ID 178) (referred to as BCY8277) ）； Ac-(Sequence ID 179) (referred to as BCY8163); Ac-[B-Ala][Sar10]-(Sequence ID 179) (referred to as BCY8276) ）； [B-Ala][Sar10]-(Sequence ID 179) (referred to as BCY8269); Ac-(Sequence ID 180) (referred to as BCY8174); Ac-(Sequence ID 181) (referred to as BCY8175); Ac-(Sequence ID 182) (referred to as BCY8176); Ac-(Sequence ID 183) (referred to as BCY8177); Ac-(Sequence ID 184) (referred to as BCY8178); Ac-(Sequence ID 185) (referred to as BCY8180); Ac-(Sequence ID 186) (referred to as BCY8181); Ac-(Sequence ID 187) (referred to as BCY8182); Ac-(Sequence ID 188) (referred to as BCY8183); Ac-(Sequence ID 189) (referred to as BCY8184); [B-Ala][Sar10]-(Sequence ID 189) (referred to as BCY8235); Ac-(Sequence ID 190) (referred to as BCY8185); Ac-(Sequence ID 191) (referred to as BCY8186); Ac-(Sequence ID 192) (referred to as BCY8187); Ac-(Sequence ID 193) (referred to as BCY8188); Ac-(Sequence ID 194) (referred to as BCY8189); Ac-(Sequence ID 195) (referred to as BCY8191); Ac-(Sequence ID 196) (referred to as BCY8192); Ac-(Sequence ID 197) (referred to as BCY8193); Ac-(Sequence ID 198) (referred to as BCY8194); Ac-(Sequence ID 199) (referred to as BCY8211); Ac-(Sequence ID 200) (referred to as BCY8212); Ac-(Sequence ID 201) (referred to as BCY8213); Ac-(Sequence ID 202) (referred to as BCY8214); [B-Ala][Sar10]-(Sequence ID 202) (referred to as BCY8231); Ac-(Sequence ID 203) (referred to as BCY8215); Ac-[B-Ala][Sar10]-(Sequence ID 208) (referred to as BCY8279) ）； Ac-[B-Ala][Sar10]-(Sequence ID 209) (referred to as BCY8280) ）； [B-Ala][Sar10]-(Sequence ID 209) (referred to as BCY8273); Ac-[B-Ala][Sar10]-(Sequence ID 210) (referred to as BCY8281) ）； Ac-(Sequence ID 211) (referred to as BCY8831); [B-Ala][Sar10]-(Sequence ID 212) (referred to as BCY8238); (Sequence ID 215) (referred to as BCY11415); [PYA][B-Ala][Sar10]-(Sequence ID 215) (referred to as BCY11942) (to be done); and (Sequence ID 216) (referred to as BCY11414); In particular, Ac-[B-Ala][Sar ５ ] - (Sequence No. 169) (BCY8122 and (To be called); Ac-(Sequence ID 169) (referred to as BCY8126); (Sequence ID 169) (referred to as BCY8116); Fluorescein (SEQ ID NO: 169) (referred to as BCY8205); and [B-Ala][Sar10]-(Sequence ID 169) (referred to as BCY8234); In particular, [B-Ala][Sar10]-(Sequence ID 169)(BCY8234). A peptide ligand according to claim 4, comprising an amino acid sequence selected from the above.

10. A-(Sequence ID 1)-A(80-09-02-N002 or referred to as BCY428) ）； Fl-A-(Sequence ID 1)-A (referred to as 80-09-02-N006); Ac-(Sequence ID 1) (also known as 80-09-02-N008 or BCY7390) ； Ac-[dD]-(Sequence ID 1) (referred to as BCY7606); A-(Sequence ID 2)-A (referred to as 80-09-02-N003 or BCY429) ； (1-Na)A-(Sequence ID 1)-A(80-09-02-N009 or BCY74) (referred to as 20); (2-Na)A-(Sequence ID 1)-A(80-09-02-N010 or BCY74) (referred to as 21); (33DPA)A-(Sequence ID 1)-A(80-09-02-N011 or BCY74) (referred to as 22); (44BPA)A-(Sequence ID 1)-A(80-09-02-N012 or BCY75) (referred to as 21); Ac-(Sequence ID 3) (referred to as 80-09-02-N017); Ac-(Sequence ID 4) (referred to as 80-09-02-N018); Ac-(Sequence ID 5) (also known as 80-09-02-N019 or BCY7537) ； Ac-(Sequence ID 6) (referred to as 80-09-02-N020); Ac-(Sequence ID 7) (also known as 80-09-02-N021 or BCY7539) ； Ac-(Sequence ID 8) (also known as 80-09-02-N022 or BCY7540) ； Ac-(Sequence ID 9) (referred to as 80-09-02-N023); Ac-(pCoF)-(Sequence ID 1) (referred to as 80-09-02-N044); Ac-(Sequence ID 10) (referred to as 80-09-02-N045); Ac-(Sequence ID 11) (referred to as 80-09-02-N046 or BCY7657) ）； Ac-(Sequence ID 12) (referred to as 80-09-02-N047 or BCY7658) ）； Ac-(Sequence ID 13) (referred to as 80-09-02-N048 or BCY7659) ）； Ac-(Sequence ID 14) (referred to as 80-09-02-N049); Ac-(Sequence ID 15) (referred to as 80-09-02-N050 or BCY7661) ）； SDN-(Sequence ID 15)-A (referred to as BCY3387); Ac-(Sequence ID 16) (referred to as 80-09-02-N051 or BCY7662) ）； Ac-(Sequence ID 17) (referred to as 80-09-02-N052); Ac-(Sequence ID 18) (referred to as 80-09-02-N053); Ac-(Sequence ID 19) (referred to as 80-09-02-N054 or BCY7665) ）； Ac-(Sequence ID 20) (referred to as 80-09-02-N055 or BCY7666) ）； Ac-(Sequence ID 21) (referred to as 80-09-02-N056); A-(Sequence ID 1)-TNK(80-09-02-T01-N001 or BCY338) (referred to as 5); A-(Sequence ID 1)-TN(HArg)(80-09-02-T01-N003 or B (referred to as CY7281); A-(Sequence ID 1)-TN(D-K)(80-09-02-T01-N004 or BC) (referred to as Y7282); A-(Sequence ID 22)-TNK (referred to as 80-09-02-T01-N005); A-(Sequence ID 23)-TNK (referred to as 80-09-02-T01-N006); Ac-(Sequence ID 1)-TNK(80-09-02-T01-N011 or BCY73) (referred to as 91); A-(Sequence ID 24)-TNK(80-09-02-T01-N012 or BCY73) (referred to as 42); A-(Sequence ID 25)-TNK(80-09-02-T01-N014 or BCY73) (referred to as 44); A-(Sequence ID 1)-ANK(80-09-02-T01-N016 or BCY734) (referred to as 6); A-(Sequence ID 1)-[dA]NK (referred to as BCY7367); A-(Sequence ID 1)-TAK(80-09-02-T01-N017 or BCY734) (referred to as 7); A-(Sequence ID 1)-T[dA]K (referred to as BCY7368); A-(Sequence ID 1)-TNA(80-09-02-T01-N018 or BCY734) (referred to as 8); A-(Sequence ID 1)-TN[dA] (referred to as BCY7369); Ac-[pCoPhe]-(Sequence ID 1) (referred to as BCY7656); A-(Sequence ID 6)-TNK(80-09-02-T01-N020 or BCY735) (referred to as 4); A-(Sequence ID 26)-TNK(80-09-02-T01-N022 or BCY73) (referred to as 52); A-(Sequence ID 27)-TNK(80-09-02-T01-N026 or BCY73) (referred to as 56); A-(Sequence ID 28)-TNK(80-09-02-T01-N027 or BCY73) (referred to as 57); A-(Sequence ID 29)-TNK(80-09-02-T01-N041 or BCY73) (referred to as 72); A-(Sequence ID 30)-TNK(80-09-02-T01-N042 or BCY74) (referred to as 24); A-(Sequence ID 31)-A(referred to as 80-10-00 or BCY488); A - (Sequence ID 32) - A (referred to as BCY432); DDW-(Sequence ID 32)-A(referred to as 80-10-11-T01 or BCY433) (ru); VDW-(Sequence ID 33)-A(referred to as 80-10-12-T01 or BCY462) (ru); QKW-(Sequence ID 34)-A(referred to as 80-10-13-T01 or BCY3400) (to be); Q[HArg]W-(Sequence ID 34)-A (referred to as BCY7278); Q[K(Ac)]W-(Sequence ID 34)-A (referred to as BCY7280); [Ac]QKW-(Sequence ID 34) (referred to as BCY7392); Q[dK]W-(Sequence ID 34)-A (referred to as BCY7426); Ac-AKW-(Sequence ID 34) (referred to as BCY7622); Ac-QAW-(Sequence ID 34) (referred to as BCY7623); Ac-QKA-(Sequence ID 34) (referred to as BCY7624); Ac-[dA]KW-(Sequence ID 34) (referred to as BCY7634); Ac-Q[dA]W-(Sequence ID 34) (referred to as BCY7635); Ac-QK[dA]-(Sequence ID 34) (referred to as BCY7636); Ac-Q[dD]W-(Sequence ID 34) (referred to as BCY7993); Ac-QK[1Naal]-(Sequence ID 34) (referred to as BCY7996); Ac-QK[2Na]-(Sequence ID 34) (referred to as BCY7997); Ac-(Sequence ID 34) (referred to as BCY8044); A-(Sequence ID 43)-A(referred to as BCY430); A-(Sequence ID 44)-A(referred to as BCY431); A-(Sequence ID 58)-PQA (referred to as BCY3401); QKW-(Sequence ID 65)-A (referred to as BCY7279); Ac-QKW-(Sequence ID 103) (referred to as BCY7625); Ac-QKW-(Sequence ID 104) (referred to as BCY7627); Ac-QKW-(Sequence ID 105) (referred to as BCY7628); Ac-QKW-(Sequence ID 106) (referred to as BCY7631); Ac-QKW-(Sequence ID 107) (referred to as BCY7632); Ac-QKW-(Sequence ID 108) (referred to as BCY7639); Ac-QKW-(Sequence ID 109) (referred to as BCY7640); Ac-QKW-(Sequence ID 110) (referred to as BCY7643); Ac-QKW-(Sequence ID 153) (referred to as BCY7998); Ac-QKW-(Sequence ID 154) (referred to as BCY8000); A-(Sequence ID 35)-A(referred to as 80-11-00 or BCY471); A-(Sequence ID 36)-A(referred to as 80-11-01 or BCY472); A-(Sequence ID 37)-SRF(referred to as 80-11-08-T01 or BCY3406) (to be); Ac-(Sequence ID 37)-SRF (referred to as BCY7393); DDA-(Sequence ID 45)-A (referred to as BCY3386); DTA-(Sequence ID 46)-A (referred to as BCY3388); DSE-(Sequence ID 47)-A (referred to as BCY3389); HDA-(Sequence ID 48)-A (referred to as BCY3390); MDT-(Sequence ID 49)-A (referred to as BCY3391); DPG-(Sequence ID 50)-A (referred to as BCY3392); HDS-(Sequence ID 51)-A (referred to as BCY3393); (D-H)DS-(Sequence ID 51)-A (referred to as BCY7272); A-(Sequence ID 52)-TDK (referred to as BCY3394); A-(Sequence ID 53)-LKD (referred to as BCY3395); A-(Sequence ID 54)-TTA (referred to as BCY3396); A-(Sequence ID 55)-QME (referred to as BCY3397); A-(Sequence ID 56)-LSE (referred to as BCY3398); A-(Sequence ID 57)-STD (referred to as BCY3399); A-(Sequence ID 59)-TNK (referred to as BCY7265); Ac- (Sequence ID 59) (referred to as BCY7660); A-(Sequence ID 60)-TNK (referred to as BCY7266); Ac-(Sequence ID 60) (referred to as BCY7616); HDS-(Sequence ID 61)-A (referred to as BCY7273); HDS-(Sequence ID 62)-A (referred to as BCY7274); HDS-(Sequence ID 63)-A (referred to as BCY7275); HDS-(Sequence ID 64)-A (referred to as BCY7276); A-(Sequence ID 66)-TNK (referred to as BCY7349); A-(Sequence ID 67)-TNK (referred to as BCY7350); Ac-(Sequence ID 67) (referred to as BCY7538); A-(Sequence ID 68)-TNK (referred to as BCY7359); A-(Sequence ID 69)-TNK (referred to as BCY7360); A-(Sequence ID 70)-TNK (referred to as BCY7361); A-(Sequence ID 71)-TNK (referred to as BCY7365); A-(Sequence ID 72)-TNK (referred to as BCY7370); Ac-(Sequence ID 73) (referred to as BCY7535); Ac-(Sequence ID 74) (referred to as BCY7536); Ac-(Sequence ID 75) (referred to as BCY7541); [B-Ala] [Sar ５ ]- (Sequence ID 76) (referred to as BCY7556); Ac-[B-Ala][Sar ５ ]- (Sequence ID 76) (referred to as BCY7558); [B-Ala] [Sar ５ ]- (Sequence ID 77) (referred to as BCY7557); Ac-[B-Ala][Sar ５ ]- (Sequence ID 77) (referred to as BCY7559); Ac-(Sequence ID 78) (referred to as BCY7580); Ac-(Sequence ID 79) (referred to as BCY7581); Ac-(Sequence ID 80) (referred to as BCY7582); Ac-(Sequence ID 81) (referred to as BCY7584); Ac-(Sequence ID 82) (referred to as BCY7585); Ac-(Sequence ID 83) (referred to as BCY7588); Ac-(Sequence ID 84) (referred to as BCY7589); Ac-(Sequence ID 85) (referred to as BCY7590); Ac-(Sequence ID 86) (referred to as BCY7591); Ac-(Sequence ID 87) (referred to as BCY7592); Ac-(Sequence ID 88) (referred to as BCY7593); Ac-(Sequence ID 89) (referred to as BCY7594); Ac- (Sequence ID 90) (referred to as BCY7595); Ac-(Sequence ID 91) (referred to as BCY7596); Ac-(Sequence ID 92) (referred to as BCY7597); Ac-(Sequence ID 93) (referred to as BCY7598); Ac-(Sequence ID 94) (referred to as BCY7607); Ac- (Sequence ID 95) (referred to as BCY7608); Ac-(Sequence ID 96) (referred to as BCY7611); Ac-(Sequence ID 97) (referred to as BCY7612); Ac- (Sequence ID 98) (referred to as BCY7613); Ac-(Sequence ID 99) (referred to as BCY7614); Ac-(Sequence ID 100) (referred to as BCY7615); Ac-(Sequence ID 101) (referred to as BCY7618); Ac-(Sequence ID 102) (referred to as BCY7620); Ac-(Sequence ID 111) (referred to as BCY7663); Ac-(Sequence ID 112) (referred to as BCY7664); Ac-(Sequence ID 113) (referred to as BCY7667); Ac-(Sequence ID 114) (referred to as BCY7668); Ac-(Sequence ID 115) (referred to as BCY7765); (Sequence ID 115) (referred to as BCY7793); (MeO-dPEG12) (Sequence ID 115) (also known as BCY8087); (Carboxyfluorescein) (Sequence ID 115) (also known as BCY8208); (PEG ３ ) (PEG ３ ) (Sequence ID 115) (referred to as BCY7815); (MeO-dPEG12)(PEG3)(PEG3)(Sequence ID 115)(BCY809) (referred to as 4); Ac-DDD-(Sequence ID 115) (referred to as BCY8028); Ac-[ddD][ddD][ddD]-(Sequence ID 115) (referred to as BCY8029); [B-Ala][Sar10]-(Sequence ID 115) (referred to as BCY7814); Ac-(Sequence ID 116) (referred to as BCY7816); (MeO-dPEG12) (BCY) bound to Ac-(SEQ ID NO: 116)D-Lys6 (Also known as 8084); Ac-(Sequence ID 117) (referred to as BCY7817); Ac-(Sequence ID 118) (referred to as BCY7818); (MeO-dPEG12) bound to Ac-(SEQ ID NO: 118)Pro(4NH)1 ( (Referred to as BCY8086); Ac-(Sequence ID 119) (referred to as BCY7819); (MeO-dPEG12)(BCY80) is bound to Ac-(SEQ ID NO: 119)Lys5. (referred to as 88); Ac-(Sequence ID 120) (referred to as BCY7820); (MeO-dPEG12)(BCY80) conjugated to Ac-(SEQ ID NO: 120)Lys3 (referred to as 89); Ac-(Sequence ID 121) (referred to as BCY7821); (MeO-dPEG12)(BCY80) is bound to Ac-(SEQ ID NO: 121)Lys4. (referred to as 90); Ac-(Sequence ID 122) (referred to as BCY7822); (MeO-dPEG12)(BCY80) is bound to Ac-(SEQ ID NO: 122)Lys6. (referred to as 91); Ac-(Sequence ID 123) (referred to as BCY7876); Ac-(Sequence ID 124) (referred to as BCY7877); Ac-(Sequence ID 125) (referred to as BCY7879); Ac-(Sequence ID 126) (referred to as BCY7881); Ac-(Sequence ID 127) (referred to as BCY7883); Ac-(Sequence ID 128) (referred to as BCY7884); Ac-(Sequence ID 129) (referred to as BCY7886); Ac-(Sequence ID 130) (referred to as BCY7887); Ac-(Sequence ID 131) (referred to as BCY7889); Ac-(Sequence ID 132) (referred to as BCY7890); Ac-(Sequence ID 133) (referred to as BCY7891); Ac-(Sequence ID 134) (referred to as BCY7892); Ac-(Sequence ID 135) (referred to as BCY7894); Ac-(Sequence ID 136) (referred to as BCY7895); Ac-(Sequence ID 137) (referred to as BCY7896); Ac-(Sequence ID 138) (referred to as BCY7897); Ac-(Sequence ID 139) (referred to as BCY7902); Ac-(Sequence ID 140) (referred to as BCY7903); Ac-(Sequence ID 141) (referred to as BCY7904); Ac-(Sequence ID 142) (referred to as BCY7906); Ac-(Sequence ID 143) (referred to as BCY7907); Ac-(Sequence ID 144) (referred to as BCY7908); Ac-(Sequence ID 145) (referred to as BCY7911); Ac-(Sequence ID 146) (referred to as BCY7912); Ac-(Sequence ID 147) (referred to as BCY7913); Ac-(Sequence ID 148) (referred to as BCY7914); Ac-(Sequence ID 149) (referred to as BCY7915); Ac-(Sequence ID 150) (referred to as BCY7916); Ac-(Sequence ID 151) (referred to as BCY7973); Ac-(Sequence ID 152) (referred to as BCY7979); Ac- (Sequence ID 155) (referred to as BCY8030); Ac-(Sequence ID 156) (referred to as BCY8031); Ac-(Sequence ID 157) (referred to as BCY8032); Ac-(Sequence ID 158) (referred to as BCY8036); Ac-(Sequence ID 159) (referred to as BCY8037); Ac-(Sequence ID 160) (referred to as BCY8038); Ac-(Sequence ID 161) (referred to as BCY8039); Ac-(Sequence ID 162) (referred to as BCY8040); Ac-(Sequence ID 163) (referred to as BCY8041); Ac-(Sequence ID 164) (referred to as BCY8042); Ac-(Sequence ID 165) (referred to as BCY8042); Ac- (Sequence ID 166) (referred to as BCY8085); Ac-[B-Ala][Sar ５ ]- (Sequence ID 167) (referred to as BCY8120) ； Ac-(Sequence ID 167) (referred to as BCY8124); Ac-[B-Ala][Sar ５ ] - (Sequence ID 168) (referred to as BCY8121) ； Ac-(Sequence ID 168) (referred to as BCY8125); Ac-[B-Ala][Sar ５ ]- (Sequence ID 169) (referred to as BCY8122) ； Ac-(Sequence ID 169) (referred to as BCY8126); (Sequence ID 169) (referred to as BCY8116); Fluorescein (SEQ ID NO: 169) (also known as BCY8205); [B-Ala][Sar10]-(Sequence ID 169) (referred to as BCY8234); [PYA][B-Ala][Sar10]-(Sequence ID 169) (referred to as BCY8846) (to be); Ac-[B-Ala][Sar ５ ]- (Sequence ID 170) (referred to as BCY8123) ； Ac-(Sequence ID 170) (referred to as BCY8127); (Sequence ID 170) (referred to as BCY8206); Ac-(Sequence ID 171) (referred to as BCY8128); (Sequence ID 171) (referred to as BCY8207); [B-Ala][Sar10]-(Sequence ID 171) (referred to as BCY8232); Ac-(Sequence ID 172) (referred to as BCY8129); Ac-(Sequence ID 173) (referred to as BCY8153); Ac-(Sequence ID 174) (referred to as BCY8154); Ac-(Sequence ID 175) (referred to as BCY8157); Ac-(Sequence ID 176) (referred to as BCY8158); Ac-(Sequence ID 177) (referred to as BCY8161); Ac-[B-Ala][Sar10]-(Sequence ID 177) (referred to as BCY8278) ）； Ac-(Sequence ID 178) (referred to as BCY8162); Ac-[B-Ala][Sar10]-(Sequence ID 178) (referred to as BCY8277) ）； Ac-(Sequence ID 179) (referred to as BCY8163); Ac-[B-Ala][Sar10]-(Sequence ID 179) (referred to as BCY8276) ）； [B-Ala][Sar10]-(Sequence ID 179) (referred to as BCY8269); Ac-(Sequence ID 180) (referred to as BCY8174); Ac-(Sequence ID 181) (referred to as BCY8175); Ac-(Sequence ID 182) (referred to as BCY8176); Ac-(Sequence ID 183) (referred to as BCY8177); Ac-(Sequence ID 184) (referred to as BCY8178); Ac-(Sequence ID 185) (referred to as BCY8180); Ac-(Sequence ID 186) (referred to as BCY8181); Ac-(Sequence ID 187) (referred to as BCY8182); Ac-(Sequence ID 188) (referred to as BCY8183); Ac-(Sequence ID 189) (referred to as BCY8184); [B-Ala][Sar10]-(Sequence ID 189) (referred to as BCY8235); Ac-(Sequence ID 190) (referred to as BCY8185); Ac-(Sequence ID 191) (referred to as BCY8186); Ac-(Sequence ID 192) (referred to as BCY8187); Ac-(Sequence ID 193) (referred to as BCY8188); Ac-(Sequence ID 194) (referred to as BCY8189); Ac-(Sequence ID 195) (referred to as BCY8191); Ac-(Sequence ID 196) (referred to as BCY8192); Ac-(Sequence ID 197) (referred to as BCY8193); Ac-(Sequence ID 198) (referred to as BCY8194); Ac-(Sequence ID 199) (referred to as BCY8211); Ac-(Sequence ID 200) (referred to as BCY8212); Ac-(Sequence ID 201) (referred to as BCY8213); Ac-(Sequence ID 202) (referred to as BCY8214); [B-Ala][Sar10]-(Sequence ID 202) (referred to as BCY8231); Ac-(Sequence ID 203) (referred to as BCY8215); Ac-[B-Ala][Sar10]-(Sequence ID 208) (referred to as BCY8279) ）； Ac-[B-Ala][Sar10]-(Sequence ID 209) (referred to as BCY8280) ）； [B-Ala][Sar10]-(Sequence ID 209) (referred to as BCY8273); Ac-[B-Ala][Sar10]-(Sequence ID 210) (referred to as BCY8281) ）； Ac-(Sequence ID 211) (referred to as BCY8831); [B-Ala][Sar10]-(Sequence ID 212) (referred to as BCY8238); (Sequence ID 215) (referred to as BCY11415); [PYA][B-Ala][Sar10]-(Sequence ID 215) (referred to as BCY11942) (to be done); and (Sequence ID 216) (referred to as BCY11414) A peptide ligand according to claim 4, comprising an amino acid sequence selected from the above.

11. The molecular scaffold is 1,1',1''-(1,3,5-triazinan-1,3, Claim 1, selected from 5-triyl)tripor-2-en-1-on (TATA) A peptide ligand as described in any one of items 10 to 10.

12. Pharmacologically acceptable salts are free acids or sodium, potassium, calcium, ammonia A peptide ligand according to any one of claims 1 to 11, selected from um salts.

13. The method according to any one of claims 1 to 12, wherein nectin-4 is human nectin-4. Petit ligand.

14. One or more effectors and / or functional groups conjugated, claim A drug conjugate comprising a peptide ligand as described in any one of items 1 to 13.

15. A drug condyl conjugate according to claim 14, conjugated with one or more cytotoxic agents. Gate.

16. The cytotoxic agent is selected from MMAE or DM1, and is particularly MMAE, according to the claim. Drug conjugates as described in item 15.

17. The cytotoxic agent is MMAE, and the conjugate is -PABC-Cit-Va l-Glutaryl- or -PABC-cyclobutyl-Ala-Cit-βAla-, for example ba-PABC-Cit-Val-Glutaryl-(where PABC is p-aminobenzyl) The drug controller according to claim 16 further comprises a linker selected from (representing a carbamate). Jugate.

18. The cytotoxic agent is DM1, and the conjugate is -SPDB-(SO ３ H) - (In the formula, SPDB is N-succinimidyl 3-(2-pyridyldithio)propionate) The drug conjugate according to claim 16, further comprising a linker which represents ().

19. BCY7683, BCY7825, BCY7826, BCY8245, BCY8253 , BCY8254, BCY8255, BCY8549, BCY8550, BCY8783 and one of BCY8784, for example BCY7683, BCY7825, BCY 7826, BCY8245, BCY8253, BCY8254, BCY8255, BCY A selection from 8783 and BCY8784, particularly BCY8245, claims 14 to 1 A drug conjugate as described in any one of item 8.

20. The peptide ligand according to any one of claims 1 to 13 or claims 14 to 19 A drug conjugate as described in any one of the paragraphs, in one or more pharmaceutically acceptable excipients A pharmaceutical composition containing a combination of agents.

21. The pharmaceutical composition according to claim 20, further comprising one or more therapeutic agents.

22. Used in the prevention, suppression, or treatment of diseases or disorders mediated by Nectin-4. A drug conjugate according to any one of claims 14 to 19 for the purpose of...

23. A method for preventing, suppressing or treating cancer, the method described in any one of claims 14 to 19 The procedure includes the step of administering the drug conjugate to a patient who requires it. However, a method is used to identify an increase in the copy number variation (CNV) of nectin-4.